GLP-1 dose escalation follows a fixed schedule set by the FDA label, not a number you or your clinician pick freely: every approved semaglutide and tirzepatide product starts low and steps up on a timed interval to limit nausea while the drug reaches a dose that actually drives weight loss.
- GLP-1 dosing follows a fixed, FDA-set schedule — not a number patients or clinicians pick freely
- Semaglutide titrates 0.25mg to 2.4mg, and tirzepatide titrates 2.5mg to 15mg, both on a four-week minimum interval per step
- Skipping titration steps is the leading cause of severe nausea and vomiting, not the drug itself
- Full titration to maintenance dose takes 16-20 weeks for most patients
- Reaching the top labeled dose isn't mandatory — many patients plateau successfully at a lower dose
- Missing more than one consecutive weekly dose often means restarting titration at a lower step
TL;DR
The GLP-1 dosing schedule for semaglutide (Wegovy) runs 0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg weekly, with each step held for four weeks minimum. Tirzepatide (Zepbound) runs 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, then 15mg weekly on the same four-week cadence. Verdict: follow the label interval, don't jump doses to chase faster results — most GI side effects in 2026 patient data trace back to skipped titration steps, not the drug itself.
Semaglutide vs. Tirzepatide Titration Schedule
Four-week minimum hold at each step
| Step | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| 1 | 0.25mg | 2.5mg |
| 2 | 0.5mg | 5mg |
| 3 | 1mg | 7.5mg |
| 4 | 1.7mg | 10mg |
| 5 | 2.4mg (maintenance) | 12.5mg |
| 6 | — | 15mg (maintenance) |
Why this matters
Dose escalation exists because GLP-1 receptor agonists slow gastric emptying, and a stomach that hasn't adjusted to 0.25mg semaglutide will not tolerate 1mg. The tirzepatide dosing schedule published by Eli Lilly and the semaglutide schedule from Novo Nordisk both build in a four-week hold at each rung specifically to let receptor tolerance catch up before the next increase. Rushing the schedule doesn't get you to your maintenance dose faster in any meaningful sense — it gets you to the ER with dehydration from uncontrolled vomiting, which is the single most common reason patients quit GLP-1 therapy in the first 60 days.
Rushing the schedule doesn't get you to your maintenance dose faster in any meaningful sense — it gets you to the ER with dehydration from uncontrolled vomiting, which is the single most common reason patients quit GLP-1 therapy in the first 60 days.
The schedule also isn't optional cosmetics. Clinicians titrate because the maintenance dose (2.4mg semaglutide, 15mg tirzepatide) is where the metabolic effect — appetite suppression, insulin sensitivity, slowed gastric emptying — actually plateaus in the clinical trial data. Undertitrating means you never reach a dose that works. Overtitrating means you never tolerate the dose long enough to stay on it.
What you'll need
- A prescription for semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) from a licensed prescriber
- A titration schedule from your clinician — this should be a specific week-by-week plan, not a vague "increase when ready"
- A weekly injection routine (same day, same general time)
- A way to log symptoms — nausea, GI changes, appetite, weight — weekly
- Baseline labs before starting: fasting glucose or HbA1c, lipid panel, and kidney function at minimum
- Four to five months of patience — full titration to maintenance dose takes 16-20 weeks for most patients
The steps
1. Start at the lowest FDA-approved dose
Semaglutide starts at 0.25mg weekly. Tirzepatide starts at 2.5mg weekly. Neither starting dose is intended to produce meaningful weight loss — it's a tolerance dose, designed to let your GI system adapt without triggering severe nausea. Expect mild nausea in the first week and little to no measurable weight change; that's the expected outcome, not a sign the drug isn't working.
Common mistake: patients assume the starting dose "isn't doing anything" and ask to skip ahead. Don't. The four-week hold at 0.25mg or 2.5mg is doing real physiological work you can't see on a scale yet.
2. Hold each dose for four weeks minimum
Every labeled titration step for both drugs is a four-week interval — no shorter. Your clinician may extend a hold to six or eight weeks if you're still nauseated at week four, but the interval never compresses below four weeks regardless of how well you're tolerating the current dose.
This is where self-directed dosing goes wrong most often: patients feel fine at week two and move up early. The GI adaptation curve for these drugs runs on a slower timeline than symptom relief does, so "feeling fine" at week two doesn't predict tolerance at the next dose.
3. Track side effects before every increase
Before any dose increase, your clinician should ask about nausea frequency, vomiting, constipation or diarrhea, and appetite change over the prior week. If nausea is still occurring most days at the end of a four-week hold, the standard move is to repeat that dose for another four weeks rather than escalate.
Patients managing GI side effects should read the specific protocol for managing nausea on semaglutide before assuming a dose increase is the next move — sometimes the fix is meal timing or portion size, not a higher dose.
Common mistake: attributing nausea to "the wrong drug" and switching between semaglutide and tirzepatide instead of just holding the current dose longer.
4. Escalate only when tolerated
Moving to the next dose (0.5mg to 1mg semaglutide, or 5mg to 7.5mg tirzepatide, for example) should happen only after four weeks of manageable side effects — not zero side effects, manageable ones. Mild nausea that resolves within a day of the injection is typically fine to escalate through; nausea that persists for three or more days a week is not.
Expected outcome by this point: measurable appetite reduction, some early weight change (commonly 2-4% of body weight by week 12 across published trial data), and side effects that are present but not disruptive to daily function.
5. Inject on a fixed weekly schedule
Both drugs are once-weekly subcutaneous injections, and consistency matters more than the exact day you pick. Injecting on the same day each week — Monday morning, for instance — keeps drug levels steady and makes it easier to track which week of a titration step you're in.
If you're self-administering at home, the technique details in injecting semaglutide at home cover rotation sites (abdomen, thigh, upper arm) and needle handling — site rotation reduces injection-site irritation, which is a separate issue from GI side effects and gets confused with it often.
6. Reach maintenance dose deliberately
Maintenance is 2.4mg for semaglutide and 15mg for tirzepatide, though not every patient needs to reach the top dose. Some patients plateau in weight loss and tolerate side effects well at 1.7mg semaglutide or 10mg tirzepatide, and clinicians will sometimes hold there rather than push to the labeled maximum if the lower dose is already producing the target result.
By 2026, most DPC and telehealth GLP-1 protocols treat the top label dose as a ceiling, not a mandatory destination — the right maintenance dose is the lowest one that keeps producing results with tolerable side effects.
The right maintenance dose is the lowest one that keeps producing results with tolerable side effects.
7. Reassess and adjust with your clinician at every step
Every dose change should involve a check-in, not just a refill. Labs (typically every 3-6 months), weight trend, and symptom review should all factor into whether you escalate, hold, or in some cases step back down a dose if side effects become disruptive.
Labs (typically every 3-6 months), weight trend, and symptom review should all factor into whether you escalate, hold, or in some cases step back down a dose if side effects become disruptive.
Troubleshooting
- Nausea persists past week 3 of a hold: don't escalate. Repeat the dose, adjust meal size and fat content, and consider an antiemetic if your clinician approves one.
- Constipation worsens with each increase: increase fluid and fiber intake proactively before each dose step, not reactively after symptoms start.
- Weight loss stalls at a stable dose: this is common at the 8-12 week mark on a given dose and doesn't automatically mean you need a higher dose — see the specific breakdown of a GLP-1 plateau before assuming escalation is the fix.
- You missed more than one weekly dose: don't resume at your last dose. Most protocols require restarting at a lower step if more than two consecutive doses were missed, since GI tolerance can regress.
- Side effects appear worse on tirzepatide than they did on semaglutide (or vice versa): this happens and isn't a sign of doing anything wrong — the two drugs act on different receptor combinations (GLP-1 alone versus GLP-1/GIP dual agonism) and tolerance varies by patient.
- You're tempted to buy compounded product to "control your own titration": dosing accuracy on compounded formulations varies by pharmacy, and self-directed titration without lab monitoring removes the safety check that catches problems early.
Tools and resources
- A titration calendar or app to log injection day, dose, and symptoms week to week
- Baseline and follow-up labs ordered by your prescribing clinician
- A clinician who reviews your dose schedule at each step rather than auto-refilling
- A structured plan for eating on the medication, since appetite changes fast once you clear the first two dose steps
What to do next
Once your dose schedule is mapped out, the next decision most patients face is which GLP-1 to start with in the first place. The full comparison of tirzepatide vs. semaglutide breaks down trial data on weight loss percentage, side effect rates, and which patients responded better to dual GIP/GLP-1 agonism versus GLP-1 alone.
FAQ
What is the standard GLP-1 dosing schedule? Semaglutide titrates 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg on a four-week interval; tirzepatide titrates 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg on the same four-week interval. Both schedules are set by FDA labeling, not by individual clinician preference.
How long does full dose escalation take? Reaching maintenance dose takes 16-20 weeks for semaglutide and up to 24 weeks for tirzepatide if all six dose steps are used, since each hold is a minimum of four weeks.
Can you skip dose steps to reach maintenance faster? No — skipping steps is the most common cause of severe nausea and vomiting on GLP-1 therapy, and it doesn't accelerate weight loss meaningfully faster than following the schedule.
What happens if you miss a dose during titration? A single missed dose within a few days of schedule is usually fine to resume at the same dose; missing more than one consecutive week often means restarting at a lower dose under clinician guidance.
Do you have to reach the maximum dose? No. Many patients plateau in results at 1.7mg semaglutide or 10mg tirzepatide and stay there rather than pushing to 2.4mg or 15mg, especially if side effects are already at the edge of tolerable.
Is the dosing schedule the same for men and women? Yes — the FDA titration schedule doesn't differ by sex; individual tolerance and target maintenance dose can still vary based on labs and response.
How much weight loss should you expect by the end of titration? Trial data commonly shows 5-10% body weight loss by the time patients reach maintenance dose, with continued loss over the following months at a stable dose.
Should nausea get worse with each dose increase? Some increase in nausea at each step is expected and typically resolves within days; nausea that worsens progressively and doesn't settle by the end of a four-week hold is a sign to repeat the dose rather than advance.
One last thing
The detail most patients miss in 2026: the four-week hold isn't a minimum you're free to extend at will without telling anyone — it's a checkpoint your clinician is supposed to review before every single increase, which is exactly the kind of step that gets skipped when a GLP-1 prescription comes from an app with no human reviewing labs or symptoms between refills.
Related guides
- What to do when GLP-1 weight loss stalls
- Tirzepatide vs. semaglutide: which works better for weight loss
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/